RHB-204
Pulmonary Nontuberculous Mycobacteria (NTM) disease
Planned Phase 3Active
Key Facts
Indication
Pulmonary Nontuberculous Mycobacteria (NTM) disease
Phase
Planned Phase 3
Status
Active
Company
About RedHill Biopharma
RedHill Biopharma is a publicly traded, Israel-based biopharmaceutical company with a mission to improve lives through innovative medicines targeting gastrointestinal diseases, infectious diseases, and oncology. The company has built a deep pipeline of late-stage clinical candidates, with a particular strategic focus on developing oral, broad-acting antiviral therapies for pandemic preparedness and medical countermeasures. RedHill operates with commercial infrastructure in both Israel and the United States, aiming to bring novel treatments to market for conditions with high unmet need.
View full company profile